Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.

van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, van der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Bapat B, van der Kwast TH, Zlotta AR.

BJU Int. 2012 Oct;110(8):1169-76. doi: 10.1111/j.1464-410X.2012.10996.x. Epub 2012 Mar 27.

2.

A new and highly prognostic system to discern T1 bladder cancer substage.

van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA, Zlotta AR.

Eur Urol. 2012 Feb;61(2):378-84. doi: 10.1016/j.eururo.2011.10.026. Epub 2011 Oct 25.

PMID:
22036775
3.

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC.

PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821.

4.

Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.

Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, Zwarthoff EC.

Clin Cancer Res. 2010 Jun 1;16(11):3011-8. doi: 10.1158/1078-0432.CCR-09-3013. Epub 2010 Apr 19.

5.

Pathological stage review is indicated in primary pT1 bladder cancer.

van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, Bangma CH, Jewett MA, Zlotta AR.

BJU Int. 2010 Jul;106(2):206-11. doi: 10.1111/j.1464-410X.2009.09100.x. Epub 2009 Dec 9.

6.

Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.

van der Aa MN, Steyerberg EW, Bangma C, van Rhijn BW, Zwarthoff EC, van der Kwast TH.

J Urol. 2010 Jan;183(1):76-80. doi: 10.1016/j.juro.2009.08.150.

PMID:
19913254
7.

Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?

de Bekker-Grob EW, van der Aa MN, Zwarthoff EC, Eijkemans MJ, van Rhijn BW, van der Kwast TH, Steyerberg EW.

BJU Int. 2009 Jul;104(1):41-7. doi: 10.1111/j.1464-410X.2008.08323.x. Epub 2008 Dec 19.

8.

The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.

Kompier LC, van der Aa MN, Lurkin I, Vermeij M, Kirkels WJ, Bangma CH, van der Kwast TH, Zwarthoff EC.

J Pathol. 2009 May;218(1):104-12. doi: 10.1002/path.2507.

PMID:
19156776
9.

Sexual function of patients under surveillance for bladder cancer.

van der Aa MN, Bekker MD, van der Kwast TH, Essink-Bot ML, Steyerberg EW, Zwarthoff EC, Sen FE, Elzevier HW.

BJU Int. 2009 Jul;104(1):35-40. doi: 10.1111/j.1464-410X.2008.08333.x. Epub 2009 Jan 14.

10.

Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).

van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, van Exsel AJ, Kirkels WJ, Bangma C, van der Kwast TH.

Eur Urol. 2009 Mar;55(3):659-67. doi: 10.1016/j.eururo.2008.05.001. Epub 2008 May 15.

PMID:
18501499
11.

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.

Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC.

Eur Urol. 2008 Oct;54(4):835-43. doi: 10.1016/j.eururo.2007.12.026. Epub 2007 Dec 26.

PMID:
18166262
12.

Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison.

van der Aa MN, Steyerberg EW, Sen EF, Zwarthoff EC, Kirkels WJ, van der Kwast TH, Essink-Bot ML.

BJU Int. 2008 May;101(9):1106-10. Epub 2007 Sep 20.

13.

Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature.

van Geel AN, den Bakker MA, Kirkels W, Horenblas S, Kroon BB, de Wilt JH, Eggermont AM, Mooi WJ, van der Aa MN.

Urology. 2007 Jul;70(1):143-7. Review.

PMID:
17656225
14.

A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.

van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC.

Clin Cancer Res. 2005 Nov 1;11(21):7743-8.

15.

A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation.

van der Aa MN, van Leenders GJ, Steyerberg EW, van Rhijn BW, Jöbsis AC, Zwarthoff EC, van der Kwast TH.

Hum Pathol. 2005 Sep;36(9):981-6.

PMID:
16153461

Supplemental Content

Loading ...
Support Center